Here’s What Analysts Are Saying About Taysha Gene Therapies (TSHA)

Group 1 - Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is considered a strong buy stock under $5, with a Buy rating maintained by Needham and a price target of $10 [1] - The company announced the dosing of the first patient in the REVEAL pivotal trial for TSHA-102, which is expected to evaluate the treatment for Rett syndrome, with enrollment progressing across multiple sites [1][2] - The REVEAL pivotal trial and ASPIRE trial dosing is anticipated to be completed by Q2 2026, with long-term safety and efficacy data updates expected in H1 2026 [2] Group 2 - Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for monogenic diseases affecting the central nervous system [3]